South Delhi Pharma, New Delhi, India
COPIKTRA (duvelisib), capsules for oral use
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.
COPIKTRA is a prescription medicine. COPIKTRA is used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma.
INDICATIONS AND USAGE
COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with:
• Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.
• Relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
DOSAGE FORMS & STRENGTHS
Capsules: 25 mg, 15 mg
Manufactured By: Verastem, Inc. (Verastem
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “COPIKTRA (duvelisib), capsules” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed. It is taken by mouth.
It is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed. Further trials are ongoing to confirm benefits as of 2019.
